| 2024/04/19 19:50:19 | |
|---|---|
| Price | |
| 251.05 EUR | |
| Difference | 1.70% (4.20) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | Tradegate |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 132,274 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 250.65 EUR (300) |
| Ask (Ask size) | 251.55 EUR (300) |
| Open | 246.10 EUR |
| High | 251.65 EUR |
| Low | 244.25 EUR |
| Close (prev. day) | 246.85 EUR |
| VWAP | 246.45476 EUR |
| Volume (pcs) | 1,743 |
| Trading volume | 429,570.65 |
| Number of trades | 54 |
| Last size | 10 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: AMGEN INC. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/01/23 |
|
Global Equity Ratings |
|
| 2024/04/19 19:50:19 | |
|---|---|
| Price | |
| 251.05 EUR | |
| Difference | 1.70% (4.20) |
General attributes
| ISIN | US0311621009 |
| Symbol | AMGN |
| Exchange | Tradegate |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 132,274 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | 250.65 EUR (300) |
| Ask (Ask size) | 251.55 EUR (300) |
| Open | 246.10 EUR |
| High | 251.65 EUR |
| Low | 244.25 EUR |
| Close (prev. day) | 246.85 EUR |
| VWAP | 246.45476 EUR |
| Volume (pcs) | 1,743 |
| Trading volume | 429,570.65 |
| Number of trades | 54 |
| Last size | 10 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -8.30% | +10.00% | +15.65% |
| Perf (abs.) | -22.35 | +22.45 | +33.40 |
| Beta | 0.77 | 0.58 | 0.41 |
| Volatility | 22.52 | 22.22 | 22.33 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 249.12 EUR (1,520) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 252.22 EUR (2,113) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 262.81 EUR (2,432) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 242.69 EUR (2,277) |
| YTD High | date | 308.00 EUR (2024/02/05) |
| YTD Low | date | 245.40 EUR (2024/03/18) |
| 52 Weeks High | date | 308.00 EUR (2024/02/05) |
| 52 Weeks Low | date | 197.50 EUR (2023/06/02) |
All listings for AMGEN INC.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/04/19 | 17:35 | 249.25 EUR | 0.10 | 33 |
| Vienna Stock Exchange | 2024/04/19 | 17:32 | 249.00 EUR | 0.00 | 2 |
| Tradegate | 2024/04/19 | 19:50 | 251.05 EUR | 0.43 | 54 |
| Stuttgart | 2024/04/19 | 19:27 | 250.45 EUR | 0.01 | 9 |
| SIX Swiss Exchange | 2022/11/14 | 17:36 | 180.00 CHF | 0.00 | 1 |
| SIX Swiss Exchange | - | - | - | 0.00 | - |
| Nasdaq | 2024/04/19 | 20:38 | 267.25 USD | 367.55 | 30,995 |
| Munich | 2024/04/19 | 08:03 | 246.25 EUR | 0.00 | 1 |
| London Stock Exchange | 2024/04/19 | 17:35 | 265.50 USD | 0.00 | 2 |
| Hong Kong Stock Exchange | 2024/02/16 | 02:15 | 1,850.00 HKD | - | - |
| Hanover | 2024/04/19 | 08:05 | 245.00 EUR | 0.00 | 1 |
| Hamburg | 2024/04/19 | 08:00 | 245.00 EUR | 0.00 | 1 |
| Frankfurt | 2024/04/19 | 16:26 | 249.00 EUR | 0.03 | 5 |
| Euronext Milan MTF Trading After Hours | 2024/03/18 | 20:28 | 250.00 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2024/04/19 | 17:44 | 248.40 EUR | 0.01 | 4 |
| Duesseldorf | 2024/04/19 | 19:30 | 250.50 EUR | 0.00 | 5 |
| Berlin | 2024/04/19 | 08:08 | 245.10 EUR | 0.00 | 1 |
Company Logo
Contact Details
| AMGEN INC. |
| - - |
| One Amgen Center Drive - 91320-1799 Thousand Oaks |
| Telefon: +1-805-447-1000 |
| Fax: +1-805-447-1010 |
| E-mail: - |
PDF Downloads
| Company report: AMGEN INC. | |
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA. |
Members of Management Board
| Brian Druker | Member of Board of Directors |
| Michael Drake | Member of Board of Directors |
| Omar Ishrak | Member of Board of Directors |
| Robert Williams | Member of Board of Directors |
| Ronald Sugar | Member of Board of Directors |
| Tyler Jacks | Member of Board of Directors |
| Wanda Austin | Member of Board of Directors |
| Amy Miles | Member of Board of Directors |
| Charles Holley | Member of Board of Directors |
| Ellen Kullman | Member of Board of Directors |
| Greg Garland | Member of Board of Directors |
| Robert Eckert | Member of Board of Directors |
| Robert A. Bradway | Chairman of Managing Board |
| David M. Reese | Member of Executive Committee |
| Jackie Elbonne | Member of Executive Committee |
| James Bradner | Member of Executive Committee |
| Jonathan Graham | Member of Executive Committee |
| Mike Zahigan | Member of Executive Committee |
| Murdo Gordon | Member of Executive Committee |
| Paul Burton | Member of Executive Committee |
| Peter Griffith | Member of Executive Committee |